Yag Laser Vitreolysis Program

A grant from industry makes participation in this program free-of-charge, but only 40 openings are left, so call +1 714-901-7777 to schedule

J. Sebag, MD, FACS, FRCOphth, FARVO

Senior Research Scientist, Doheny Eye Institute, UCLA

Professor of Clinical Ophthalmology, Stein Eye Institute, Geffen School of Medicine, UCLA

Founding Director, VMR Institute for Vitreous Macula Retina

President, VMR Consulting, Inc.

7677 Center Avenue, # 400

Huntington Beach, CA 92647             




Over the past years, the VMR Research Foundation has been at the forefront of efforts to shed light on vision-degrading myodesopsia (VDM) and elevate its status to a recognized eye disease deserving of effective and safe treatments.

Through extensive research endeavors, the foundation has made significant strides in understanding the underlying causes and mechanisms of eye floaters, paving the way for innovative approaches to treatment. Spearheaded by Dr. Sebag and his dedicated research team, these efforts have yielded promising advancements in the quest for safer and less invasive treatment modalities.

For an in-depth look at the foundation’s future research plans and strategies, you can open and download the PDF file provided here:

Central to the foundation’s mission is the VDM Project, which serves as a vital resource for individuals worldwide affected by eye floaters. By providing up-to-date information on the latest research findings and developments, the VDM Project empowers sufferers to stay informed and engaged in their journey towards better vision health. Through comprehensive outreach efforts, the project strives to foster a global community of support and collaboration among patients, researchers, and healthcare professionals.

Your support is crucial in advancing our mission.

Please consider making a donation today to help fund critical research initiatives, enabling us to accelerate progress towards safer and more effective treatments for VDM:

Together, we can make a difference in the fight against vision-degrading myodesopsia.


Dear Sufferers,

Recently Dr. Sebag released a brief interview with some important updates for the VDM PROJECT.

The VMR RESEARCH FOUNDATION, along with prominent partners and doctors, is working to make progress and get closer to a better solution to diagnose and treat eye floaters.

In this interview, Dr. Sebag answered some of the most relevant questions from the community and shared some significant considerations on the recognition of VDM as a significant disease by medical practitioners vs. being considered simply a nuisance.

In the upcoming months, we plan to involve doctors and experts from the Scientific Advisory Board to begin discussing different points of view and possible solutions to cope, treat and cure eye floaters.

 We have uploaded the video of Dr. Sebag’s interview to the VDM PROJECT YouTube account.

 You can access it here: CLICK HERE

 Let’s unite for clear vision!

 The VMR Research Foundation is grateful for your continued support.

Your contribution matters and represents a positive step forward toward a better and safe treatment for eye floaters.

Eye Floaters Prevalence Study

Eye Floater Prevalence Study

The VDM Project is currently in the process of commissioning a study on the prevalence of vitreous floaters among adults in the United States.

Although the survey instrument will not be administered in a clinical setting and will therefore not allow for patients to undergo the objective testing that could be used to establish a formal diagnosis of vision-degrading myodesopsia, its purpose is nevertheless to ascertain just how many individuals are afflicted by floaters and how many report that their floaters are serious enough to affect their daily activities and quality of life. 

Existing research on this question suffers from clear problems of selection bias [1], and so the VDM Project will be working with a company experienced in collecting data for social scientific studies to ensure a representative sample that allows for valid statistical inference.

Although ophthalmologists (and retina specialists in particular) anecdotally report that floaters are very common, especially among older adults, these reports somewhat paradoxically seem to coexist with a widespread perception among clinicians that disability resulting from floaters is very rare, if it even occurs at all [2].


Some authors have even expressed surprise that studies of vitrectomy for the treatment of floaters have been able to find enough patients whose condition was serious enough to warrant surgical intervention [3].

This new prevalence study will finally provide vital data that has long been lacking on the societal impact of vitreous floaters.

Even for many other conditions that are comparatively understudied, such as tinnitus [4], fibromyalgia [5], or myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) [6], there at least exist credible estimates of population prevalence. 
These estimates will be critically important in helping us to convince government and industry to devote desperately needed funding to develop better and safer cures.
Please support the VDM PROJECT to help us find a safer and better cure for Eye Floaters


Let’s Unite For clear Vision

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693028/
[2] https://www.escrs.org/publications/EUROTIMES/11July-August/vitrectomyforfloaters.pdf (“Arguing against [the use of vitrectomy for treating floaters] was Stanley Chang MD, Edward Harkness Professor of Ophthalmology, Columbia University in New York… ‘I do believe there is disability associated with floaters, but it is relatively rare.'”)
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996761/ (“The authors of these studies cite impairment in activities of daily living (Mason et al and Sebag et al), contrast sensitivity (Sebag et al) or well-being (Sebag et al) as the primary inclusion criteria for surgical intervention. It is somewhat surprising, however, that hundreds of patients presenting to these centers, over a short time period, would be impaired to the extent that PPV is required”)
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812683/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575027/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331450/